OmniAb (NASDAQ:OABI) Insider Sells $11,883.00 in Stock

OmniAb, Inc. (NASDAQ:OABI) insider Charles Berkman sold 6,990 shares of OmniAb stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $1.70, for a total value of $11,883.00. Following the completion of the transaction, the insider directly owned 383,623 shares of the company’s stock, valued at approximately $652,159.10. This represents a 1.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

OmniAb Price Performance

Shares of OmniAb stock opened at $1.71 on Friday. The stock has a market capitalization of $246.17 million, a price-to-earnings ratio of -2.95 and a beta of 0.13. The firm’s fifty day simple moving average is $1.88 and its 200-day simple moving average is $1.76. OmniAb, Inc. has a 12 month low of $1.22 and a 12 month high of $4.02.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of OmniAb in a report on Monday, December 22nd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $6.67.

Hedge Funds Weigh In On OmniAb

A number of large investors have recently bought and sold shares of OABI. The Manufacturers Life Insurance Company lifted its position in OmniAb by 20.5% in the second quarter. The Manufacturers Life Insurance Company now owns 44,809 shares of the company’s stock valued at $78,000 after purchasing an additional 7,624 shares during the period. Rhumbline Advisers raised its holdings in OmniAb by 6.0% during the second quarter. Rhumbline Advisers now owns 160,728 shares of the company’s stock worth $280,000 after purchasing an additional 9,163 shares during the last quarter. Osaic Holdings Inc. boosted its position in OmniAb by 214.4% during the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock worth $25,000 after purchasing an additional 9,716 shares in the last quarter. AQR Capital Management LLC acquired a new stake in OmniAb in the first quarter valued at $25,000. Finally, BNP Paribas Financial Markets increased its position in shares of OmniAb by 92.5% in the third quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock valued at $35,000 after buying an additional 10,438 shares in the last quarter. Hedge funds and other institutional investors own 72.08% of the company’s stock.

About OmniAb

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.